T2 Biosystems, Inc., a company specializing in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced that they will be reporting their financial results for the first quarter of 2024 and providing business updates after the market closes on Monday, May 6, 2024. A conference call hosted by company management will begin at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call can access a live and archived webcast of the event on the Investor page of the T2 Biosystems website at www.t2biosystems.com in the Events & Presentations section. To listen to the conference call via phone, participants can dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 160751, approximately ten to five minutes prior to the scheduled start time.
T2 Biosystems is dedicated to improving patient care and reducing the cost of care by enabling clinicians to effectively treat patients faster than ever before. Their products, such as the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel, utilize the proprietary T2 Magnetic Resonance (T2MR) technology. With an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel, T2 Biosystems continues to innovate in the field of rapid diagnostics. For more information, visit www.t2biosystems.com.
For investor inquiries, please contact Philip Trip Taylor at the Gilmartin Group by emailing ir@T2Biosystems.com or calling 415-937-5406.